Introduction {#sec1}
============

With the advent of next-generation sequencing technologies, the number of characterized ncRNA classes in eukaryotic cells has dramatically increased ([@ref1]. Recently, tRNA-derived non-coding RNAs (ncRNAs), a novel heterogeneous class of ncRNAs originating from tRNA processing, have been characterized. Indeed, it has been shown that tRNA-derived ncRNAs are not mere byproducts of random tRNA cleavage, rather they may actively play roles in several biological phenomena, such as ribosome biogenesis, retrotransposition, virus infections, apoptosis and cancer pathogenesis ([@ref4]. Furthermore, some classes of tRNA-derived ncRNAs have been shown to bind AGO and PIWI proteins, potentially acting as post- or pre-transcriptional regulators of gene expression ([@ref9], [@ref14].

Accumulating evidence also suggests the presence of functional tRNA-derived ncRNAs in human biological fluids, such as urine and serum from cancer patients ([@ref15].

tRNA biogenesis begins with the transcription of tRNA genes by RNA polymerase III leading to 'precursor tRNA' (pre-tRNA). Such molecules undergo a maturation process inside the nucleus, where 5′ leader and 3′ trailer sequences are cleaved by ribonuclease P (RNase P) and ribonuclease Z (RNase Z), respectively ([@ref15], [@ref20]. In the last few years, several kinds of tRNA-derived ncRNAs have been discovered. However, a unique classification is still missing. A common grouping of such molecules is based on the location they originate from within the tRNA gene. tRNA-derived ncRNAs can, therefore, be divided into two main classes: (i) tsRNAs, which derive from pre-tRNA and (ii) stress-induced tRNA fragments (tiRNAs), together with tRFs, which derive from mature tRNA ([@ref13].

tsRNA are produced inside the nucleus and result from the cleavage of the pre-tRNAs 3′ trailer sequence by RNases Z. They usually begin after the 3′-end of mature tRNAs and are characterized by a polyuracil sequence at their 3′-ends ([@ref13].

tiRNAs, which have a length of \~28--36 nt, are produced in the cytoplasm via specific cleavage of the anticodon loop of mature tRNAs by Rny1p and angiogenin (ANG) in yeast and mammalians cells, respectively ([@ref15], [@ref26], [@ref27]. This class is comprised of 5'-tiRNA and 3'-tiRNA, in reference to the 5′ or 3′ half of the mature tRNA they derive from, respectively ([@ref15].

tRFs, ranging from 14 to 30 nt in length, are derived from mature tRNA ([@ref15], [@ref23], [@ref28]. Three types of tRFs have been discovered to date: (i) tRF-5s; (ii) tRF-3s; and (iii) i-tRFs ([@ref29], [@ref30]. tRF-5s are generated in the cytoplasm by Dicer-mediated cleavage of the mature tRNA D-loop ([@ref29], [@ref31]. tRF-3s are produced in the cytoplasm via cleavage of the T-loop in mature tRNAs operated by Dicer, ANG and other members of the RNase A superfamily. They are fragments originating from mature tRNA 3′-ends, and include the final CCA sequence ([@ref28], [@ref29], [@ref32]. Finally, i-tRFs are enriched within the internal regions of mature tRNAs, usually straddling the anticodon region ([@ref29], [@ref33]. It is important to highlight that in literature and in some databases, tsRNAs (which derive from 3′ trailer sequence of pre-tRNAs) are also termed tRF-1s ([@ref30], [@ref34], [@ref35].

Additionally, a recently investigated group of tRFs, namely 5′ leader-exon tRFs, has been described in a study associating them with the loss of spinal motor neurons in CLP1-kinase dead mice ([@ref36]. These fragments span from the beginning of the 5′ end of pre-tRNAs to the 5′ end of mature tRNAs and are produced inside the nucleus. However, their biogenesis and function remain still unknown, and consequently, this class has not currently been completely characterized ([@ref36].

Our study aims at the identification of tRNA-derived ncRNAs in the National Cancer Institute 60 (NCI-60) cell lines and The Cancer Genome Atlas (TCGA) samples. This has been done through the development of a custom bioinformatics pipeline for the identification of tsRNAs (also termed tRF-1), tRFs (tRF-5s and tRF-3s) and 5′ leader RNAs in small non-coding RNA-seq (sncRNA-seq data).

NCI-60 is a panel of 60 human cancer cell lines derived from nine different cancer types (leukemia, colon, lung, central nervous system, renal, melanoma, ovarian, breast and prostate) ([@ref37], while TCGA is a collection of samples covering 33 different tumor types with more than 11 000 cancer patients.

We collected all the profiling results in an intuitive, publicly available database, tRFexplorer (<https://trfexplorer.cloud/>). Our database allows users to search for tRNA-derived ncRNAs, visualize their expression profiles in both NCI-60 cell lines and TCGA patient cohorts, apply differential expression (DE) analysis on TCGA samples and correlate tRNA-derived ncRNA expression profiles with several covariates, such as NCI-60 omics data, TCGA mRNA and miRNA expressions, and TCGA patients survival data, in order to better aid in the identification of mechanisms in which such molecules might be involved in.

Material and methods {#sec2}
====================

tRNA-derived ncRNAs identification pipeline {#sec3}
-------------------------------------------

The identification of tsRNAs, 5′ leader RNAs and tRFs in sncRNA-seq datasets is a complex process, since such small fragments may be mapped to multiple DNA regions. For this purpose, we implemented a conservative pipeline to get an accurate estimation of tsRNAs, 5′ leader RNAs and tRF expression. First, we assembled a custom annotation of the reference human genome (hg19) containing only known tsRNAs and tRFs. We included all tRF-5s, tRF-3s and tRF-1s from tRFdb (<http://genome.bioch.virginia.edu/trfdb/>) ([@ref34], all tsRNA identified by ([@ref8] and the 20-nt upstream region of tRNA human genes for the 5′ leader RNAs. Human tRNA genes were taken from GtRNAdb (<http://gtrnadb.ucsc.edu/>) ([@ref40]. Subsequently, we examined sncRNA-seq datasets of NCI-60 cell lines as provided by the sequence read archive (SRA) (PRJNA390643) ([@ref39], as well as sncRNA-seq datasets on TCGA. In [Table 1](#TB1){ref-type="table"}, we provide a list of NCI-60 cell lines and the SRA datasets, while in [Table 2](#TB2){ref-type="table"}, it lists the analyzed TCGA cancer types with their relative numbers of tumor and control samples. Raw FASTQ files were pre-processed for adaptor removal and quality filtering by applying Trim Galore (<https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/>) tuned for sncRNA-seq (Phred quality score ≥20). Trim Galore is a wrapper for Cutadapt ([@ref41] and FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>), which is used as a consistent method to apply quality filtering and adaptor trimming. Filtered FASTQ files were then aligned to a reference human genome (hg19) using TopHat version 2.1.0 ([@ref42] as well as to our custom annotation file. Read quantification has been performed with HTSeq version 0.10.0 ([@ref43]. In this phase, all ambiguously mapped reads were removed for a more accurate and conservative analysis. Data analysis was performed with R version 3.5.1. Raw counts were normalized with two different normalization methods: transcripts per million mapped reads (TPM) ([@ref44] and reads per million mapped reads (RPM) ([@ref45].$$\documentclass[12pt]{minimal}
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###### 

List of NCI-60 cell lines tested and the relative SRA dataset

  Cell line     Type of cancer   SRA dataset
  ------------- ---------------- -------------
  T-47D         BREAST           SRR5689215
  MCF-7         BREAST           SRR5689213
  MDA-MB-231    BREAST           SRR5689212
  BT-549        BREAST           SRR5689211
  HS-578T       BREAST           SRR5689210
  SF-295        CNS              SRR5689217
  SF-268        CNS              SRR5689216
  SF-539        CNS              SRR5689214
  U251          CNS              SRR5689209
  SNB-75        CNS              SRR5689208
  SNB-19        CNS              SRR5689175
  HCT-116       COLON            SRR5689179
  HT-29         COLON            SRR5689178
  KM12          COLON            SRR5689177
  SW-620        COLON            SRR5689176
  COLO 205      COLON            SRR5689174
  HCT-15        COLON            SRR5689173
  HCC2998       COLON            SRR5689172
  MOLT-4        LEUKEMIA         SRR5689193
  K-562         LEUKEMIA         SRR5689192
  SR            LEUKEMIA         SRR5689191
  RPMI 8226     LEUKEMIA         SRR5689190
  CCRF-CEM      LEUKEMIA         SRR5689183
  HL-60(TB)     LEUKEMIA         SRR5689182
  LOX-IMVI      MELANOMA         SRR5689197
  MALME-3M      MELANOMA         SRR5689196
  MDA-MB-435    MELANOMA         SRR5689195
  M14           MELANOMA         SRR5689194
  SK-MEL-5      MELANOMA         SRR5689189
  SK-MEL-28     MELANOMA         SRR5689188
  UACC-62       MELANOMA         SRR5689167
  UACC-257      MELANOMA         SRR5689164
  SK-MEL-2      MELANOMA         SRR5689165
  NCI-H522      NSCLC            SRR5689201
  NCI-H460      NSCLC            SRR5689200
  HOP 62        NSCLC            SRR5689171
  NCI-H23       NSCLC            SRR5689170
  EKVX          NSCLC            SRR5689169
  HOP 92        NSCLC            SRR5689168
  A549          NSCLC            SRR5689166
  NCI-H322M     NSCLC            SRR5689163
  NCI-H226      NSCLC            SRR5689162
  OVCAR-5       OVARIAN          SRR5689207
  OVCAR-4       OVARIAN          SRR5689206
  OVCAR-8       OVARIAN          SRR5689205
  OVCAR-3       OVARIAN          SRR5689204
  NCI/ADR-RES   OVARIAN          SRR5689203
  IGR-OV1       OVARIAN          SRR5689202
  SK-OV-3       OVARIAN          SRR5689198
  DU-145        PROSTATE         SRR5689199
  PC-3          PROSTATE         SRR5689187
  A498          RENAL            SRR5689186
  CAKI-1        RENAL            SRR5689185
  786-0         RENAL            SRR5689184
  SN12C         RENAL            SRR5689181
  TK-10         RENAL            SRR5689180
  UO-31         RENAL            SRR5689161
  ACHN          RENAL            SRR5689160
  RXF393        RENAL            SRR5689159

###### 

List of analyzed TCGA cancer types with their relative numbers of tumor and control samples

  Tumor type   Tumor name                                                          Tumor samples   Control samples
  ------------ ------------------------------------------------------------------ --------------- -----------------
  ACC          Adrenocortical carcinoma                                                 79        
  BLCA         Bladder urothelial carcinoma                                             408              19
  BRCA         Breast invasive carcinoma                                               1101              113
  CESC         Cervical squamous cell carcinoma and endocervical adenocarcinoma         306               3
  CHOL         Cholangiocarcinoma                                                       36                9
  COAD         Colon adenocarcinoma                                                     459              41
  DLBC         Lymphoid neoplasm diffuse large B-cell lymphoma                          48        
  ESCA         Esophageal carcinoma                                                     185              11
  GBM          Glioblastoma multiforme                                                  167       
  HNSC         Head and neck squamous cell carcinoma                                    522              44
  KICH         Kidney chromophobe                                                       66               25
  KIRC         Kidney renal clear cell carcinoma                                        534              72
  KIRP         Kidney renal papillary cell carcinoma                                    291              32
  LAML         Acute myeloid leukemia                                                   173       
  LGG          Brain lower grade glioma                                                 533       
  LIHC         Liver hepatocellular carcinoma                                           374              50
  LUAD         Lung adenocarcinoma                                                      517              59
  LUSC         Lung squamous cell carcinoma                                             501              51
  MESO         Mesothelioma                                                             87        
  OV           Ovarian serous cystadenocarcinoma                                        309       
  PAAD         Pancreatic adenocarcinoma                                                179               4
  PCPG         Pheochromocytoma and paraganglioma                                       184               3
  PRAD         Prostate adenocarcinoma                                                  498              52
  READ         Rectum adenocarcinoma                                                    166              10
  SARC         Sarcoma                                                                  263               2
  SKCM         Skin cutaneous melanoma                                                  472               1
  STAD         Stomach adenocarcinoma                                                   414              35
  TGCT         Testicular germ cell tumors                                              139       
  THCA         Thyroid carcinoma                                                        513              59
  THYM         Thymoma                                                                  120               2
  UCEC         Uterine corpus endometrial carcinoma                                     546              23
  UCS          Uterine carcinosarcoma                                                   57        
  UVM          Uveal melanoma                                                           80        
                                                                                    **10 327**         **720**

All tsRNAs, 5′ leader RNAs and tRFs with average log2 TPM less than 1 were removed. A summary of our full pipeline is shown in [Figure 1](#f1){ref-type="fig"}.

![A summary of the tRNA-derived ncRNAs identification pipeline from RAW FASTQ files to normalized counts matrix.](baz115f1){#f1}

Implementation of tRFexplorer {#sec4}
-----------------------------

All identified tsRNAs, 5′ leader RNAs and tRFs with their expression profiles have been integrated in a novel database named tRFexplorer. tRFexplorer enables users to visualize the expression profile of each tRNA-derived ncRNA in both NCI-60 cell lines and TCGA samples (33 cancer types). Furthermore, it uses the R package limma ([@ref46] to perform DE analysis on TCGA data. Interactive visualization of its results has been implemented through the R package Glimma ([@ref47]. Our database allows users to conduct correlation analysis of tRNA-derived ncRNAs expression in NCI-60 with all data available on CellMiner ([@ref48], [@ref49]. Correlation analysis with genes and miRNA expression profiles, as well as patient survival, of TCGA samples has also been implemented.

tRFexplorer was developed by employing PHP and R for its backend, and Javascript and React for the main user interface. All omics data and compound activities used for the correlation analysis were obtained from CellMiner ([@ref48], [@ref49]. In [Table 3](#TB3){ref-type="table"}, we list all CellMiner datasets.

###### 

A list of CellMiner datasets with their description

  **CellMiner dataset**                                          **Description**
  -------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  DNA CNV-Roche NibleGen 385 K aCGH                              385 K element tiling array based on NCBI Build 35 of the human genome (HG17) and re-mapped to NCBI Build 35 (HG19); 50-mer tiling with a median probe spacing of 6000 bp.
  DNA CNV-combined aCGH                                          Probe intensities combined from four platforms: agilent human genome CGH Microarray 44A, Nimblegen HG19 CGH 385 K WG Tiling v2.0, Affymetrix GeneChip human mapping 500 k array set and Illumina Human1Mv1_C Beadchip
  DNA single nucleotide polymorphism (SNP) per gene-Affy 500 K   This platform is used for whole-genome association studies. It is comprised of two arrays which enable genotyping of more than 500 000 SNPs.
  DNA SNP per gene-Illumina 1 M SNP                              BeadChip array based on Illumina's infinium assay with probes for 1 072 820 SNPs
  DNA methylation-Illumina 450 K                                 Approximately 450 000 probes querying the methylation status of CpG sites within and outside of genes.
  RNA Affy HG-U133_AB                                            Human genome U133. 44 000 probeset 2-chip set. Gene expression.
  RNA Affy HG-U133 Plus 2.0                                      Aproximately 47 000 transcripts
  RNA Affy HuEx 1.0                                              1 432 155 probesets for all human gene exons
  RNA agilent human mRNAs                                        44 000 probes for approximately 41 000 genes, with four arrays spotted on each slide.
  RNA expression combined z-scores                               Gene expressions
  RNA agilent human miRNAs                                       15 000 probes for 723 human and 76 human viral miRNA's. Each slide contains eight arrays.
  RNA microRNA OSU V3 Chip                                       Custom microarray developed at Microarray Shared Resource Comprehensive Cancer Center, OSU microarray facility. It contains 11 k probes (two technical replicates) for murin and human microRNAs together with hypothetical microRNAs and control probes.
  RNA ABC transporters array                                     47 specific oligonucleotide probes were designed for each of the ABC transporters using DNAStar Primer Select. Expression levels were measured by real-time quantitative RT-PCR using the LightCycler RNA Amplification SYBR Green kit and a LightCycler machine.
  RNA OSU transporter array                                      Spotted 70-mer microarray
  Protein lysate array                                           Reverse-phase lysate arrays (RPLA) for 162 antibodies for 94 genes. Each array included 64 lysates (60 cancer cells and 4 replicate control pools) in 10 serial 2-fold dilutions.
  Compound activities                                            Negative log10 (GI50) values of sulforhodamine B assay for \~ 50 K compounds, including more than 20 000 that passed quality control, 158 Food and Drug Administration approved and 79 clinical trial drugs. Higher values equate to higher sensitivity of cell lines.

Genomic viewer for tRNA-derived ncRNAs visualization is based on JBrowse ([@ref50]. JBrowse is a fast and interactive genomic viewer built entirely with new HTML5 technology. We customized our browser by allowing users to search for both tRNAs or tRNA-derived ncRNAs using both genomic coordinates or identifiers.

Results {#sec5}
=======

tRNA-derived ncRNAs identified {#sec6}
------------------------------

In our study, we employed NCI-60 ([@ref39] and TCGA sncRNA-seq datasets to identify tsRNAs, 5′ leader RNAs and tRFs, assessing their expression profile. In these datasets, we were able to identify 322 expressed tRNA-derived ncRNAs in NCI-60 (11 tRF-5s, 55 tRF-3s, 107 tsRNAs and 149 5′ leader RNAs) and 232 expressed tRNA-derived ncRNAs (53 tRF-5s, 58 tRF-3s, 63 tsRNAs and 58 5′ leader RNAs) in TCGA. A number of tsRNAs, 5′ leader RNAs and tRFs identified across NCI-60 cell lines and TCGA samples present noticeable expression levels. Moreover, all small RNA sequences mapped within four specific regions: 5′ end (tRF-5) and 3′ end (tRF-3) of mature tRNA, and 3′ trailer (tsRNA or tRF-1) and 5′ leader (5′ leader RNAs) regions of primary tRNA genes. If these small RNA sequences were the result of a random degradation process, their ends would be equally distributed along the lengths of tRNA genes with a comparable frequency ([@ref34], [@ref35]. In addition, we can observe that each TCGA cancer type (whose control samples are available) displays a different pattern of dysregulated tRNA-derived ncRNAs. Taken together, these results may suggest that these small RNAs are not fragments derived from the random cleavage of precursor and mature tRNAs, rather they are actively expressed and produced by specific ribonucleases and may be dysregulated in several human cancers. Indeed, recent evidences have shown dysregulated tRNA-derived ncRNAs in Chronic lymphocytic leukemia (CLL), colon, breast, ovary, lung and prostate cancers ([@ref8], [@ref9], [@ref11], [@ref12], [@ref51], [@ref52].

tRFexplorer database {#sec7}
--------------------

All identified sncRNAs have been integrated in a novel database named tRFexplorer. tRFexplorer is an easy-to-use, web-based database (<https://trfexplorer.cloud/>) containing tRNA-derived ncRNAs expression profiles for NCI-60 cell lines and TCGA samples, together with all omics and compound activities data available on CellMiner ([Table 3](#TB3){ref-type="table"}). Leveraging CellMiner data, tRFexplorer enables users to perform correlation analysis inferring knowledge on the biological function of such molecules. Furthermore, a module allowing DE analysis for all tRNA-derived ncRNAs in TCGA samples has been released. A detailed explanation of tRFexplorer functions is provided in the following sections.

*Browse.* In the 'Browse' section, users can search for tsRNAs, 5′ leader RNAs and tRFs by 'location' or 'expression'. Browsing by location enables users to search and visualize all tRNA-derived ncRNAs in the reference human genome ([Figure 2](#f2){ref-type="fig"}). Specifically, through the custom genome browser, it is possible to interactively search tRNA-derived ncRNAs either by genomic coordinates or by identifier.

![The genomic location of ts-106 visualized in our interactive genome viewer.](baz115f2){#f2}

Browsing by expression section enables users to filter data using at least one of the following options: (i) the type of fragment (tRF-3, tRF-5, tsRNA and 5′ leader RNAs); (ii) the amino acid carried by the pre-tRNA; (iii) the anticodon sequence; (iv) the dataset in which the fragment is expressed (TCGA tumor types or NCI-60 cell lines); and (v) the tissue subtype (normal, tumor, metastatic, recurrent, etc). It is also possible to set a minimum RPM threshold for tRNA-derived ncRNAs. The search procedure will scan our database looking for all tRNA-derived ncRNAs matching users criteria, and the results will be reported in a table.

Once results become available, users may view a page with detailed information by selecting any single result. Such page will show plots for assessing RPM expression levels in both NCI-60 ([Figure 3](#f3){ref-type="fig"}) and TCGA ([Figure 4](#f4){ref-type="fig"}). A genomic viewer will show genomic locations for each tRNA-derived fragment.

![Example of bar plot which shows tRFdb-3022a expression across NCI-60 cell line.](baz115f3){#f3}

![Example of box plot which shows tRFdb-3022a expression across TCGA cancer types.](baz115f4){#f4}

*Correlation analysis.* In the 'Correlation Analysis' section, users can perform correlation analyses of all identified tsRNAs, 5′ leader RNAs and tRFs in NCI-60, with the omics and compound activities data available on CellMiner ([@ref48] ([Table 3](#TB3){ref-type="table"}). Correlation analysis can also be performed with mRNA/miRNA expression profiles, as well as patient survival data, of TCGA samples. Specifically, the user selects the correlation measure (Pearson or Spearman) and which dataset to consider. A list of correlated and anticorrelated tRNA-derived ncRNAs will be shown. The results can then be filtered by: (i) ncRNA name; (ii) genes, miRNAs, compound names; (iii) the genomic coordinates, when available; and (iv) the minimum correlation value. By clicking on each result, an interactive scatter plot with the data of the selected molecules will appear ([Figure 5](#f5){ref-type="fig"}).

![Example of a scatter plot which shows the correlation between the expression profile of ts-62 in NCI-60 and the expression of NOTCH4.](baz115f5){#f5}

*DE analysis.* In the 'DE analysis' section, users can perform DE analysis to discover which tsRNAs, 5′ leader RNAs and tRFs are dysregulated in TCGA tumor types. To start the analysis, users select the cancer type and one of the available covariates (gender, race, vital status, sample type or classification). It is also possible to set the maximum *P*-value and minimum log-fold-change (logFC) for the analysis. After selecting all the parameters, users must select at least one contrast to perform for the DE analysis, in association with the selected covariate. Once the analysis is launched, a list of differentially expressed tRNA-derived ncRNAs with their logFC and FDR adjusted *P*-value will be shown together with an interactive volcano plot to better visualize their DE ([Figure 6](#f6){ref-type="fig"}). By clicking on a specific point in the plot or row in the table, a swarm plot of the expression values will also be shown ([Figure 6](#f6){ref-type="fig"}).

![Vulcano plot which shows the differentially expressed tRNA-derived ncRNAs in TCGA Lung Squamous Cell Carcinoma (LUSC) when compared with control samples, and a swarm plot which specifically shows the difference in the expression profile of one (tRFdb-5015a) of the differentially expressed tRNA-derived ncRNAs.](baz115f6){#f6}

Comparison between tRFexplorer and MINTbase V.2.0 {#sec8}
-------------------------------------------------

We compared data and features of tRFexplorer with MINTbase V2.0 ([@ref53], another established database of tRNA-derived ncRNAs in TCGA. MINTbase V2.0 has a user-friendly graphical user interface and it combines data from 768 different human datasets and 11.198 TCGA small RNA-Seq datasets. MINTbase V2.0, however, is focused only on tRFs, i-tRF and tiRNAs (or tRNA halves). Indeed, only tRNA-derived ncRNAs formed from mature tRNAs are taken into account. tsRNAs and 5′ leader RNAs, coming from pre-tRNAs, are not available in MINTbase V.2.0. On the other hand, tRFexplorer does not store tiRNAs and i-tRF. [Table 4](#TB4){ref-type="table"} reports the tRNA-derived ncRNAs classes stored in tRFexplorer and MINTbase V.2.0, respectively.

Concerning tRNA-derived ncRNAs identification methods, we aim to stress an important difference between tRFexplorer and MINTbase. The tRFs available in MINTbase V2.0 have been identified with MINTmap ([@ref54] prediction algorithm. Instead, tRFexplorer uses well-known mapping and counting tools (see Materials and Methods 2.1) to identify the RNA reads mapping on our custom annotated human genome. Specifically, we used the genomic coordinates obtained from tRFdb ([@ref34] for the identification of tRF-5s and tRF-3s and the genomic coordinates published on ([@ref8] for the identification of the experimental validated tsRNAs. Finally, for the 5′ leader RNAs identification, we counted the RNA reads mapped on the 20-nt upstream regions of all human tRNA genes. We used this strategy since tRFdb nomenclature is the most widely used for tRFs in literature while we used the genomic coordinates present on ([@ref8] for tsRNAs since they were identified by *in vitro* experiments and not with in-silico prediction.

Moreover, one of the aims of our work was to report only high confident tRFs and 5′ leader RNAs and *in vitro* validated tsRNAs. Specifically, we reported 399 tRNA-derived ncRNAs on tRFexplorer (some of them are expressed both on NCI-60 and TCGA datasets, while others are specifically expressed either on NCI-60 or TCGA datasets). On the contrary, a very large number of unique sequences reported on MINTbase V.2.0 (28.824) were identified through the prediction algorithm MINTmap. We noticed that many tRFs, i-tRFs and tiRNAs reported in MINTbase V.2.0 are expressed with 1 RPM in a single dataset (1 out of 12.023). Specifically, 6.248 out of 28.824 unique sequences present on MINTbase V.2.0 are expressed in only one dataset (1 out of 12.023), while 15.717 out of 28.824 unique sequences are expressed in only 10 out of 12.023 datasets. It is also well established that tRF-5s and tRF-3s have well-defined length and they can be further stratified in tRF-5a (14--16 nts), tRF-5b (22--24 nts), tRF-5c (28--30 nts), tRF-3a (about 18 nts) and tRF-3b (about 22 nts) subclasses accordingly to their size ([@ref13], [@ref15], [@ref30], [@ref32]. Moreover, tRF-5s and tRF-3s are produced by ribonuclease cleavage in the D-loop and T-loop region, respectively ([@ref13], [@ref15], [@ref30], [@ref32]. In MINTbase V2.0, we noticed that 252 out of 2304 tRF-5s and 1439 out of 4028 tRF-3s are longer than 31 and 25 nt, respectively, while 248 out of 2304 tRF-5s and 284 out of 4028 tRF-3s have sequences that do not end at their cleavage site in the D-loop or T-loop, respectively, but they overlap the anticodon region.

###### 

tRNA-derived ncRNAs classes stored in tRFexplorer and MINTbase V2.0

                                    tRFexplorer   MINTbase V.2.0
  -------------------------------- ------------- ----------------
  5′ Leader RNAs                         x       
  tsRNAs                                 x       
  tRF (tRF-5s and tRF-3s)                x              x
  tiRNAs (tiRNA-5s and tiRNA-3s)                        x
  i-tRF                                                 x

Indeed, the total number of tRNAs-derived ncRNAs in MINTbase V2.0 looks quite high if we consider that in the human genome, there are only about 400 tRNA genes and that many 5′ and 3′ end regions of mature tRNAs are shared across different tRNAs, and therefore, a single tRFs, with the same sequence, can be produced by different tRNAs. For this reason, to avoid overestimation, we decided to keep very low the number of identified tRNA-derived ncRNAs.

Finally, we conducted a comparison between the features of tRFexplorer vs those available in MINTbase V.2.0. tRFexplorer implements several specific functions such as: explore the genomic location of tRNA-derived ncRNAs through an interactive genomic browser; perform DE analysis in all TCGA samples; and finally correlation analysis with different TCGA (mRNAs and miRNAs expression) and CellMiner (omics data and compounds activities) data. Moreover, different high-quality plots are available on tRFexplorer to better understand the results. A detailed comparison of the features is shown in [Table 5](#TB5){ref-type="table"}.

###### 

Features comparison of tRFexplorer and MINTbase V2.0

                                                            tRFexplorer                                                  MINTbase V.2.0
  --------------------------------------------------------- ------------------------------------------------------------ -----------------------------
  Datasets                                                  TCGA, NCI-60                                                 TCGA, human datasets
  Total number datasets                                     12.187 + 59 = 12.246                                         12.023
  tRNA-derived ncRNAs identification methods                Mapping and counting on custom annotated human genome        Prediction based on MINTmap
  tRNA-derived ncRNAs filtering expression criteria         Mean Log2 TPM \> 1 across all samples                        RPM ≥ 1 in a single sample
  Unique sequences                                          399                                                          28.824
  tRFs sub-classification according to their size           Available                                                    Not available
  Normalization methods                                     TPM, RPM                                                     RPM
  Interactive genomic browser                               Available                                                    Not available
  DE analysis                                               Available                                                    Not available
  Correlation analysis                                      Available                                                    Not available
  Plot for data visualization                               Bar plot, box plot, scatter plot, volcano plot, swarm plot   Bar plot, box plot
  Other data for tRNA-derived ncRNAs correlation analysis   TCGA mRNAs and miRNAs expression, CellMiner datasets         No other data available

Discussion {#sec9}
==========

Our study aims at identifying tsRNAs, 5′ leader RNAs and tRFs in NCI-60 and TCGA small RNA-seq datasets, together with an intuitive web interface for data querying and browsing. For this purpose, we implemented a custom bioinformatics pipeline for the detection and quantification of these ncRNAs from small RNA-Seq data. Due to TCGA's large sample base, we took into consideration NCI-60 in light of its extensive use for the testing of novel compounds and the identification of drug-response biomarkers ([@ref55]. We analyzed recent versions of the NCI-60 ([@ref39] and TCGA small RNA-seq datasets to identify and establish expression profiles for tsRNAs, 5′ leader RNAs and tRFs. In these datasets, we were able to detect 322 expressed tRNA-derived ncRNAs in NCI-60 (11 tRF-5s, 55 tRF-3s, 107 tsRNAs and 149 5′ leader RNAs) and 232 expressed tRNA-derived ncRNAs in TCGA samples (53 tRF-5s, 58 tRF-3s, 63 tsRNAs and 58 5′ leader RNAs). Our reference tsRNA and tRF annotation were obtained from ([@ref8] and tRFdb ([@ref34], respectively. 5′ leader RNAs were obtained from the 20-nt upstream region of tRNA genes and named by using the tRNA identifier from which they derived.

It is noteworthy that the high expression levels of some tsRNAs, 5′ leader RNAs and tRFs in both NCI-60 and TCGA, and their DEs across TCGA cancer types indicate that these molecules are not fragments derived from the random cleavage of precursor and mature tRNAs, suggesting that such molecules may be actively expressed and produced by specific ribonucleases. Indeed, if tsRNAs, 5′ leader RNAs and tRFs were the results of a random degradation process, their ends would be equally distributed along the lengths of tRNA genes with a comparable frequency ([@ref34], [@ref35]. In our case, small RNA sequences mapped on four specific regions: 5′ end (tRF-5) and 3′ end (tRF-3) of mature tRNA, and 3′ trailer (tsRNA or tRF-1) and 5′ leader (5′ leader RNAs) regions of primary tRNA genes. Pre-tRNA molecules undergo a maturation process inside the nucleus, where 5′ leader and 3′ trailer sequences are cleaved by RNAse P and RNAse Z, respectively ([@ref15]. It is established that tsRNAs are derived from the 3′ trailer region of pre-tRNAs ([@ref9]. Conversely, the identification of small RNA sequencing reads mapping within the pre-tRNA 5′ leader genomic region represents an additional evidence of this yet poorly investigated class of tsRNAs ([@ref24], [@ref25], [@ref61]. Although some authors already reported tRNA fragments mapping between 5′ leader region and mature tRNA ([@ref36], [@ref62], our 5′ sequences are entirely located inside the pre-tRNA leader region. Furthermore, such sequences extend up to the RNAse P cleavage site, without going beyond such site. The high expression of 5′ leader RNAs and their specific ends in correspondence of RNAse P cutting site supports the hypothesis that these molecules could have a biological function, although an *in vitro* validation is still missing.

All identified tsRNAs, 5′ leader RNAs and tRFs have been stored in tRFexplorer, a novel database accessible through an easy-to-use web interface. tRFexplorer allows us to visualize the expression profile of each tsRNAs, 5′ leader RNAs and tRFs for all NCI-60 cell lines and TCGA tumor types. Furthermore, it enables DE analysis for all tumor types present in TCGA and correlation analysis with all omics and compounds activity data reported on CellMiner. The interface is comprised of three main sections: 'Browse'; 'DE Analysis'; and 'Correlation Analysis'. The 'Browse' section is used to search tsRNAs, 5′ leader RNAs and tRFs by location and expression. For each sncRNA, its expression is displayed in both NCI-60 cell lines and TCGA tumor types. Moreover, an interactive genomic viewer allows users to search and visualize all the identified tRNA-derived ncRNAs in the reference human genome. Through the DE analysis panel, users can discover which tRNA-derived ncRNAs are dysregulated in each TCGA tumor type. By selecting the cancer type to analyze and one of their variables (gender, race, vital status, sample type or classification), together with the *P*-value threshold and minimum logFC, a list of differentially expressed tRNA-derived ncRNAs with their logFC and FDR adjusted *P*-value will be shown. Volcano plots and swarm plots are also shown in order to better elucidate their DE. Finally, through the 'Correlation Analysis' panel, the user can perform correlation analyses of all identified tRNA-derived ncRNAs in NCI-60 with the omics and compound activities data available on CellMiner ([@ref48] ([Table 3](#TB3){ref-type="table"}). In addition, correlation analysis with genes, miRNA expression and patients' survival data of TCGA samples are also possible. The correlation tool will yield only the molecules that have an absolute correlation coefficient greater than 0.5. The user also has the option to select two different correlation measures (Pearson and Spearman).

The correlation analysis aids in the investigation of the biological function of tRNA-derived ncRNAs, as there is currently poor evidence in such regard. For this purpose, their correlation or anticorrelation with protein levels, mRNA and miRNA expressions, could provide a first clue regarding a potential biological pathway in which these ncRNAs may be involved.

Moreover, tRNA-derived ncRNAs showing high correlations or anticorrelations with the activity profiles (chemoresistance and chemosensitivity) of a specific antitumor compound could be selected for further studies as drug response biomarkers. Indeed, in a recent study, it has been shown that some tRFs are dysregulated in cell lines of breast cancer resistant to Trastuzumab against sensitive cell lines ([@ref63].

Finally, we compared data and features of tRFexplorer with MINTbase V2.0 ([@ref53], a database of tRNA-derived ncRNAs in TCGA. From the comparison, we can establish that, to avoid overestimation and artifacts within the databases, tRFexplorer stores less tRNA-derived ncRNAs with respect to MINTbase. On the other hand, tRFexplorer presents a more flexible interface allowing rich functional data analysis.

Conclusion {#sec10}
==========

This study introduces a novel database called tRFexplorer equipped with a Web App enabling the exploration of tRNA-derived ncRNAs expression profiles (tsRNAs, 5′ leader pre-tRNAs derived small RNAs, and tRFs) on the NCI-60 panel and TCGA samples. By exploiting DE analysis, tRFexplorer allows users to study the specific pattern of dysregulated tRNA-derived ncRNAs of each TCGA cancer type. Finally, a correlation analysis tool provided by our software may be employed as an instrument to investigate the putative biological roles of these molecules in the absence of direct experimental validation of their functions while allowing users to consider further *in vitro* and *in vivo* investigations on the most promising molecules.

Availability {#sec11}
============

tRFexplorer is available at <https://trfexplorer.cloud/>.

The results presented in this manuscript are in part based upon data generated by the TCGA Research Network: <http://cancergenome.nih.gov/> (Project \#19459 - tsRNA signature in Cancer - Consent \#73394-2).
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